Taiwan biopharma sees rush of IPOs, Nikkei Asia reports

Taiwan’s biopharma sector is seeing a rush of initial public offerings today, according to Nikkei Asia. The listing burst highlights rising investor demand for healthcare growth and puts Taipei in sharper competition with regional biotech hubs. Fresh capital could speed late-stage trials and manufacturing plans for local drug and medtech developers at a moment when global risk appetite is stabilizing.

Nikkei Asia reports multiple Taiwan biopharma companies have filed prospectuses and queued listings on the Taiwan Stock Exchange and Taipei Exchange, linking the momentum to policy support and a maturing clinical pipeline. The outlet says initial timetables and pricing details are emerging as regulators clear applications and underwriters and institutional investors build books actively. Watch for indicative pricing, oversubscription signals, and early trading performance to gauge depth of the market. [Developing. This article will be updated.]